Rapport Therapeutics (RAPP) Equity Ratio (2023 - 2026)
Rapport Therapeutics (RAPP) has 4 years of Equity Ratio data on record, last reported at 0.95 in Q1 2026.
- On a quarterly basis, Equity Ratio changed 0.13% to 0.95 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.95, a 0.13% change, with the full-year FY2025 number at 0.95, down 2.48% from a year prior.
- Equity Ratio reached 0.95 in Q1 2026 per RAPP's latest filing, roughly flat from 0.95 in the prior quarter.
- Over the last five years, Equity Ratio for RAPP hit a ceiling of 0.98 in Q3 2024 and a floor of 0.16 in Q4 2023.
- A 4-year average of 0.83 and a median of 0.95 in 2026 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: surged 688.01% in 2024, then fell 5.18% in 2025.
- Tracing RAPP's Equity Ratio over 4 years: stood at 0.16 in 2023, then soared by 688.01% to 0.97 in 2024, then decreased by 2.48% to 0.95 in 2025, then increased by 0.19% to 0.95 in 2026.
- Business Quant data shows Equity Ratio for RAPP at 0.95 in Q1 2026, 0.95 in Q4 2025, and 0.96 in Q3 2025.